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Abstract: Esophageal carcinoma is one of the deadliest cancers with highly aggressive potency, ranking as the sixth most 
common cancer among males and ninth most common cancer among females globally. Due to metastasis and invasion of 
surrounding tissues in early stage, the 5-year overall survival rate (14%) of esophageal cancer remains poor, even in com-
parison with the dismal survival rates (4%) from the 1970s. Numerous genes and proteins with abnormal expression and 
function involve in the pathogenesis of esophageal cancer, but the concrete process remains unclear. Microarray technique 
has been applied to investigating esophageal cancer. Many gene expression studies have been undertaken to look at the 
specific patterns of gene transcript levels in esophageal cancer. Human tissues and cell lines were used in these gene-
profiling studies and a very valuable and interesting set of data has resulted from various microarray experiments. These 
expression studies have provided increased understanding of the complex pathological mechanisms involved in esophag-
eal cancer. The eventual goal of microarray is to discover new markers for therapy and to customize therapy based on an 
individual tumor genetic composition. This review summarized the current state of gene expression profile studies in eso-
phageal cancer. 
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INTRODUCTION 
  As one of the deadliest cancers with highly aggressive 
potency, esophageal cancer (EC) ranks as the sixth most 
common cancer among males and ninth most common can-
cer among females globally [1]. Worldwide, EC is the sixth 
leading cause of death from cancer [2]. EC is of two main 
types, each with distinct etiological and pathological charac-
teristics. Esophageal squamous cell carcinoma (ESCC) is 
predominant type of ECs worldwide comprising more than 
90% of all cases [3]. While ESCC is prevalent in the devel-
oping world, esophageal adenocarcinoma is commonly seen 
in the developed country, usually in association with Bar-
rett's esophagus. Due to metastasis and invasion of surround-
ing tissues in early stage, the 5-year overall survival rate 
(14%) of EC remains poor, even in comparison with the dis-
mal survival rates (4%) from the 1970s [4]. Numerous genes 
and proteins with abnormal expression and function involve 
in the pathogenesis of EC, but the concrete process remains 
unclear. We still have limited understanding of the 
pathophysiology of this disease and a lack of a diagnostic 
serum marker. 
  The term DNA microarray (also called DNA chip) refers 
to the systematic arrangement of biomolecular probes such 
as DNA molecules on a solid surface. Either cDNA microar-
rays or oligonucleotidebased chips may be used for gene 
expression analysis. Microarray technique was firstly used in 
and then was utilized in the field of gene expression since  
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1995 [5]. A high-capacity system was developed to monitor 
the expression of many genes in parallel. Microarrays pre-
pared by high-speed robotic printing of complementary 
DNAs on glass were used for quantitative expression meas-
urements of the corresponding genes. Because of the small 
format and high density of the arrays, hybridization volumes 
of 2 microliters could be used that enabled detection of rare 
transcripts in probe mixtures derived from 2 micrograms of 
total cellular messenger RNA. Differential expression meas-
urements of 45 Arabidopsis genes were made by means of 
simultaneous, two-color fluorescence hybridization [5]. Mi-
croarray technique allows us to monitor the expression of 
thousands of genes simultaneously and has been used suc-
cessfully to explore the gene expression of carcinoma and 
other diseases [6-9]. 
  DNA microarray has been utilized in the studies of EC 
since 2001, several microarray studies were performed for 
investigating the gene expression profiling in EC tissue and 
cell lines [10-12]. Gene expression profiling studies promise 
to provide a more functional molecular understanding of this 
disease. In this review, we systematically examined the pub-
lished results from microarray-based outcome studies in EC. 
Moreover, we presented associations between gene expres-
sion profiles and tumor metastasis, chemoradiotherapy resis-
tance, immunotherapy and patient survival. 
GENE EXPRESSION PROFILES AND METASTASIS 
  Metastasis and invasion of surrounding organs are the 
major wrongdoers for the poor prognosis of EC. Up to date, 
the tumor, node, metastasis (TNM) staging system is still the 
primary method for determining the extent of the cancer and 
the prognosis of patients, and it often functions as a surro-Current Gene Expression Studies in Esophageal Carcinoma  Current Genomics, 2009, Vol. 10, No. 8    535 
gate for survival. However, due to the existence of undetect-
able micrometastasis and low sensitivity of clinical imaging, 
this system does not always predict prognosis accurately. 
Therefore, finding and identifing of new molecular markers 
related to the prognosis of patients is a promissing method 
for achieve more accurate clinical outcome predictions and 
treatment options of EC. 
  Lymph node metastasis, including the number and loca-
tion of lymph nodes involved, is one of the most important 
determinants in distinguishing early-stage and advanced-
stage EC. A focus in EC molecular profiling is to compare 
gene expression profiles of tumors with lymph node metasta-
sis and those without to find a signature that can predict 
lymph node status of a primary tumor. Since 2003, there 
were several studies focused on the potential specific bio-
markers for predicting and detecting the lymph node metas-
tasis in EC [13-16]. By the aid of cDNA microarray analysis, 
Kawamata  et al. [13] compared the expression profiles of 
9,206 genes in metastasizing human ESCC cell line T.Tn-
AT1 to its parental non-metastasizing cell line. They identi-
fied 34 genes showed more than 3-fold differential expres-
sion in T.Tn-AT1 cells and confirmed the expression levels 
of 14 of these genes by means of RT-PCR. The encoded pro-
teins of these genes associated with adhesion, migration, 
inflammation, proliferation and differentiation regulation. 
They hypothesed these genes might regulate the metastasis 
of ESCC, and could be predictive markers for lymph node 
metastasis. 
  After investigating the gene expression profile in tumor 
tissue of 28 cases of ESCC by cDNA microarray, Kan and 
his colleagues [14] utilized analyzing artificial neural net-
work (ANN) model to predict occurrence of lymph node 
metastasis. They found that it was difficult to extract useful 
information for the prediction of lymph node metastasis by 
clustering analysis. But systematic analysis combining Sig-
nificance Analysis of Microarrays with ANN was very use-
ful for the prediction of lymph node metastasis in ECs. This 
finding provided an useful method for the detecting the 
metastasis of lymph node in ECs. 
 Uchikado  et al. [15] used oligonucleotide DNA chips that 
included a total of 17, 086 probes to investigate the genes 
related to lymph node metastasis in ESCC. The non-
cancerous paired tissues were chosen for control and the 
pathological examination of lymph node dissection was also 
reviewed. This resulted in the identification of 43 genes that 
were overexpressed and 138 genes were down-regulated in 
ESCC compared to non-cancerous paired tissues. These al-
tering expressing genes, involved in cell-cycle and cell adhe-
sion regulation, apoptosis, and cell differentiation related. 
The expression of 5 overexpressed genes and one suppressed 
expression gene were confirmed by real-time semi-
quantitative reverse transcriptional polymerase chain reac-
tion (RT-PCR) method not only in study cases but also in 
additional 21 cases. Their result of real-time semi-
quantitative RT-PCR was in accordance with the microarray 
data.  
  Another study performed to find the relationship between 
gene expression profile and metastasis was presented by 
Wong et al. [17]. Using 15 adjacent normal/tumor-matched 
ESCC tissues as the specimens, they identified 40 up-
regulated and 95 down-regulated genes and verificated the 
microarray measurement by quantitative real-time reverse 
transcription PCR. After comparing the data with protein-
protein interaction databases, 18 genes were presumed as the 
minimal discriminators for distinguishing ESCC tumors 
from normal specimens. Ten of them were associated with 
tumor metastasis.  
  These studies not only reveal how novel insights can be 
obtained from gene expression profiling, but also highlight a 
group of highly interacting genes associated with metastasis 
in ESCC. We were able to extract some genes related to 
nodal metastasis in ESCC by microarray technique. How-
ever, further examination is necessary in other genes as well 
as the interaction between the cancer cells and the stromal 
tissues. 
GENE EXPRESSION PROFILES AND CHEMO-
THERAPY SENSITIVITY 
  Surgery remains the standard primary treatment and the 
best palliation for patients with EC. Traditional management 
of patients with localized EC has been dominated by surgical 
resection. However, the survival is still poor and many pa-
tients develop metastatic disease or locoregional recurrence 
after surgery [18]. As an alternative to resection for locore-
gional treatment of EC, there is some evidence to support 
combined chemoradiotherapy over radiotherapy alone [19].  
  Both squamous-cell carcinoma and adenocarcinoma of 
the esophagus are responsive to chemotherapeutics, thus 
making chemotherapy as an available treat of EC. According 
to previous reports of Enzinger and his colleagues, shrinkage 
of the EC by at least 50 percent may occur in 15 to 30 per-
cent of patients who are treated with fluorouracil, taxane 
(paclitaxel or docetaxel), or irinotecan [20]. More studies 
proved that similar responses was observed in 35 to 55 per-
cent of patients who received cisplatin (CDDP) in combina-
tion with these chemotherapeutics [21-26]. However, for 
many patients with EC, chemotherapy is plagued by the drug 
resistance, which can be both intrinsic and acquired. There-
fore, it is of undoubted importance to explore the mechanism 
of the resistance to chemotherapeutics in EC. 
  As one of the most widely used platinum-containing 
anticancer drugs of chemotherapy for EC, CDDP is believed 
to induce tumor cell death as a result of the formation of 
CDDP-DNA adducts, which inhibit DNA replication and 
transcription [27]. Up to date, the presence of intrinsic or 
acquired resistance to CDDP in esopgageal cancer cells re-
mains a major obstacle to successful chemotherapy. There-
fore, gaining insight of the precise mechanisms of CDDP 
resistance and reversing it would provide the new strategies 
for cancer therapy. It is known that the mechanisms of resis-
tance to CDDP are multifactorial, many genes or gene prod-
ucts have been reported to be responsible for CDDP resis-
tance [28]. And it was well known that a number of cellular 
adaptations, including reduced uptake, inactivation by glu-
tathione and other anti-oxidants, and increased levels of 
DNA repair or DNA tolerance, could cause the drug-
resistance, which may contribute to the poor survival of EC. 
  In 2001, Kihara et al. [29] used cDNA chips that in-
cluded a total of 9,216 probes to investigate the expression 
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the same adjuvant chemotherapy after removal of tumor by 
operation, and attempted to find genes associated with the 
duration of survival after surgery. By comparing expression 
profiles of those cancer tissues, they identified 52 genes that 
were likely to be correlated with prognosis and possibly with 
resistance to anticancer drugs. These genes including 
H.sapiens H4/j gene, c-erbB2 and epidermal growth factor 
receptor. 
  Toshimitsu and his colleagues [30] utilized cDNA mi-
croarray technology to explore the potential genes involved 
in acquired CDDP resistance of ESCC. They choose a 
CDDP-resistant cell line (YES-2/CDDP) as the objects, 
which show resistance to CDDP and decreasing CDDP-
accumulation compared with the parental YES-2 ESCC cell 
line. They identified 44 genes with significantly different 
expression levels between YES-2/CDDP and YES-2 cells 
and found that 15 of these 44 genes encoded ribosome-
related proteins, almost all of which were underexpressed in 
YES-2/CDDP cells. These results suggested that the ribo-
some-related genes might involve in the acquired resistance 
to CDDP in ESCC. 
  A complete pathological response to chemotherapy for 
EC is associated with favourable survival, therefore, iden-
tidication the drug-response predictor is of great importance 
to the chemotherapy for EC. However, prediction of thera-
peutic efficacy is hampered by the intricate mechanism of 
drug sensitivity. Fumoto et al. [31] used oligonucleotide 
DNA chips to identify novel potent marker genes related to 
sensitivity for CDDP and 5-Fu in ESCC cell lines. After in-
vestigating the gene expression profiles of 20 KYSE human 
ESCC cell lines and 18 tumor samples, they demonstrated 
that interferon induced transmembrane protein 1 (IFITM1) 
gene was possibly a key determinant of the CDDP sensitiv-
ity. And found that a set of the selected genes including 
IFITM1 maybe effective for predicting therapeutic responses 
to CDDP chemotherapy in EC. These results might provide a 
new method to predict the therapeutic efficacy of CDDP and 
5-Fu in EC. 
  Our previous study [32] revealed that the upregulation of 
zinc ribbon domain-containing-1 (ZNRD1) gene could sig-
nificantly enhance the tolerance of ESCC cell to CDDP. We 
investigated the gene ZNRD1-related expression profile by 
cDNA microarray analysis in ESCC cells and identified 16 
genes with significantly different expression levels. Our re-
sults suggested that and overexpression of ZNRD1 could 
enhance the resistance to CDDP in human ESCC cells by 
upregulation of excision repair cross-complementing-1 
(ERCC1) and B-cell lymphoma-2 (Bcl-2). 
 Recently,  Takashima  et al. [33] using an oligonucleotide 
microarray consisting of 34, 594 genes to identify the genes 
that are related to the sensitivity to CDDP in EC cells. The 
IC50 for CDDP was measured for 15 EC cell lines, then the 
microarray was utilized to explore the different gene expres-
sion level. They identified 37 genes were differentially ex-
pressed in the CDDP-resistant EC cell line. Their results 
might provide several candidate genes that may be associ-
ated with resistance to CDDP in EC cells, but the further 
functional studies is still necessary to confirm the possible 
effect of these genes in CDDP resistance. 
GENE EXPRESSION PROFILES AND RADIOTHER-
APY RESISTANCE 
  The use of primary radiotherapy as an alternative to sur-
gery was initially evaluated in patients with ESCC whose 
general medical condition made them poor operative candi-
dates. The most important advantage of primary radiotherapy 
is the avoidance of perioperative morbidity and mortality [4]. 
However, the resistance to radiotherapy hampered the pa-
tients acquire more excellent therapeutic efficacy and con-
tributed the poor prognosis of EC. Microarray technique 
provides a new method to gain insights into the molecular 
mechanisms underlying the effect of irradiation on EC.  
  In 2004, Bo et al. [34] used a cDNA microarray screen-
ing of more than 4,000 genes with known functions to iden-
tify genes involved in the early response to ionizing irradia-
tion on ESCCs. According to their results, there were 27 
genes overexpressed and 26 downregulated in ESCC cell 
lines after ionizing irradiation. The author utilized semiquan-
titative RT-PCR to partly identify the results of microarray. 
However, this observation can only suggest the relationship 
between these genes and the irradiation-reaction of EC cells. 
Further study is still needed to understanding of the molecu-
lar basis of radiotherapy and in developing strategies to 
augment its efficacy. 
  Fukuda and his colleagues [35] established radioresistant 
EC cell lines by applying fractionated irradiation, and then 
identified the differentially expressed genes between parent 
and radioresistant cells. Using cDNA microarray consisting 
of 21,168 genes, they identified 19 genes upregulated and 28 
downregulated common to radioresistant EC cell sublines. 
Reverse transcription-polymerase chain reaction was utilized 
to confirm that genes selected by cDNA microarray were 
overexpressed in clinical specimens of radioresistant cases. 
The upregulated genes were associated with apoptosis and 
inflammatory response (BIRC2 and COX-2), DNA metabo-
lism (CD73), and cell growth (PLAU). The function of 
downregulated genes included apoptosis (CASP6), cell ad-
hesion (CDH1 and CDH3), transcription (MLL3), and cell 
cycle (CDK6). Importantly, their results identified the rela-
tionship between COX-2 and radioation resistance proved by 
previous studies.  
 Recently,  Ogawa  et al. [36] analyzed the global gene 
expression profiles in radiosensitive and radioresistant ESCC 
cell lines using a 34, 594-spot oligonucleotide microarray. 
Totally, gene expression profiles of 13 EC cell lines were 
investigated compared with a normal esophageal epithelial 
cell line. They found the TE-11 cell line was highly sensitive 
to radiation and identified 71 candidate genes that were dif-
ferentially expressed in TE-11 by microarray analysis.  
GENE EXPRESSION PROFILES AND IMMUNO-
THERAPY 
  Up to data, the treatment of unresectable and relapsed 
ECs still remains a challenge, especially in patients acquiring 
resistance to presently available chemotherapy or radiation 
therapy regimens. Therefore, development of a new effective 
therapeutic approach such as immunotherapy is needed to 
expand treatment modalities [37, 38]. By the aids of cDNA 
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we can identified the antigens strongly and specifically ex-
pressed only in cancer cells and not in normal cell counter-
parts. And then choosing these specifical antigens as the mo-
lecular target for immunotherapy. 
  In a promising study performed at 2004 [39], Yoshitake 
and his colleagues found a novel candidate antigen, prolif-
eration potential-related protein (PP-RP) by cDNA microar-
ray analysis. And examined cytotoxicity against tumor cells 
in vitro and in vivo of cytotoxic T lymphocytes (CTLs) spe-
cific to PP-RP established from EC patients. According to 
their results, expression of PP-RP in EC cells was signifi-
cantly higher than in normal cells, and the CTLs recognizing 
PP-RP killed tumor cells in vitro and also showed tumor 
rejection effects in nude mouse engrafted human EC cells. 
This finding also proved that cDNA microarray analysis is a 
useful method to identify ideal tumor-associated antigens. 
GENE EXPRESSION PROFILES AND PATIENT 
SURVIVAL 
  During the past decades, the improvement of surgical 
skill and chemotherapeutics made the patients with EC could 
acquire better therapeutic efficacy. However, the 5-year 
overall survival rate of EC remains poor. The metastasis, 
even occuring in early stage, is the major wrongdoer of this 
depressed situation. The now modified TNM staging system 
provides adequate prognostic information for patients with 
esophageal. However, application of this staging system re-
sults in the potential overtreatment or undertreatment of a 
significant number of patients, and it can only be applied 
after complete surgical resection rather than after a presurgi-
cal biopsy. Moreover, detecting the micrometastasis still 
remains a challenge for clinicians and pathologists. There-
fore, identifing new molecular markers for prognosis could 
provide important supplement for current TNM staging sys-
tem of EC. As a high-throughput research method, microar-
ray could provide convenience for finding and identifing the 
molecular markers for estimating the patient survival. Re-
cently developed microarray technology has permitted the 
development of multi-organ cancer classifiers [40, 41] iden-
tification of tumor subclasses [42-44], discovery of progres-
sion markers [45, 46] and prediction of disease outcome in 
many types of cancer [47-49]. Therefore, by the aid of mi-
croarray analysis, potential information might also be ac-
quired for estimating the patient survival of EC. 
  Comparing to other malignancies, such as non-small cell 
lung cancer and breast cancer, there is still insufficient study 
about the relationship between altering gene expression pro-
files and patients’ survival in EC. And the well-designed 
prospective studies with large samples and factor analysis 
will help us to obtain novel insights in this field. 
CONCLUSIONS 
  Gene expression profiling has been applied in a wide 
range of EC outcome studies and has revealed hundreds of 
significantly altered expressed genes. Some of these genes 
have been further investigated and have provided increased 
understanding of the complex pathological mechanisms in-
volved in EC. However, a common problem in most pub-
lished studies is lacking evaluation of the value-added utility 
of expression profiling results in the context of known prog-
nostic factors. And due to lack of reference databases for 
comprehensive gene expression for human cancers and no 
specific group of biomarkers for the diagnosis of specific 
tumors, accurate diagnoses of individual tumors by gene 
expression profile alone are not always possible. In spite of 
these limitations, DNA microarray could be best used for 
molecular classification of EC based on genetic and biologi-
cal changes. And microarray technique will help us to obtain 
novel insights in the highly interacting genes associated with 
carcinogenesis of EC. 
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